GluLipTIn Duo Tablet 2.5/500 mg
Linagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Samchundang Pharm. Co., Ltd.
MFDS item code 202002038 · Approved 2020.03.24
This product's status changed to Expired on 2025.03.24. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise therapy to help control blood glucose levels in adults with type 2 diabetes. It is administered when a patient has never been treated with diabetes medication before or when blood glucose control is difficult with monotherapy. Additionally, it can be used as a substitute for combined treatment with Linagliptin and Metformin. If blood glucose control is insufficient even when using insulin with Metformin, this medication can be co-administered with insulin. In cases where control is difficult with the maximum recommended dose of Metformin and Empagliflozin, this medication is used alongside Empagliflozin to manage blood glucose levels. This medication is used to improve blood glucose control in various treatment situations.
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended dose of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug therapy and inadequate glycemic control with monotherapy, the initial dose is one tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to one tablet of this medicine 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should take an initial dose equivalent to their previous doses of linagliptin and metformin. 3. Patients with inadequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to be a dose similar to linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's existing metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Requiring Cautious Administration). No studies have evaluated the safety and efficacy of switching to this medicine in patients previously treated with other oral glucose-lowering agents. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function decreases to CrCl <45 ml/min or eGFR <45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Do not administer to the following patients).
This medication has been reported to cause serious side effects, including lactic acidosis, and caution is required. It should not be used in individuals with hypersensitivity to any of its components or in patients with type 1 diabetes, lactic acidosis, diabetic ketoacidosis, or diabetic precomatose state. It should also not be administered to patients with severely impaired kidney function or in conditions where acute renal function deterioration is anticipated, severe infections, or dehydration. Patients with liver dysfunction or severe gastrointestinal disorders, as well as those with acute alcohol intoxication or alcoholism, should not take this medication. Pregnant women, nursing mothers, and women who may become pregnant should not take this drug. This medication can cause hypoglycemia, so blood glucose levels should be carefully monitored, especially when used with sulfonylureas or insulin. To reduce the risk of lactic acidosis, kidney function should be regularly checked, and if any unusual symptoms occur, medical attention should be sought immediately. Patients with poor heart function should be administered this drug with caution, and it should be temporarily discontinued before and after examinations that involve iodine-containing contrast agents. It is recommended to discontinue this drug for a certain period before and after surgery. This medication may cause rare side effects such as acute pancreatitis and bullous pemphigoid, so if severe abdominal pain or skin abnormalities occur during treatment, consult a physician immediately. Vitamin B12 deficiency may occur, so it is advisable to monitor serum vitamin B12 levels during long-term use. This medication can interact with other drugs, so it is imperative to inform healthcare providers of any other medications being taken. In the elderly or children, the decision to administer this drug should consider renal function and safety. It is safer not to use this medication during pregnancy or breastfeeding. In cases of overdose, gastrointestinal decontamination and possibly hemodialysis or other treatments may be necessary. This medication should be kept out of reach of children, stored away from moisture, and not transferred to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture; therefore, it should be stored in a sealed container. It is preferable to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature. This way, the efficacy of the medication can be well preserved and deterioration prevented.
Light yellow, biconvex, oval film-coated tablet
60 tablets/bottle [(10 tablets/PTP packaging x 6)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Linagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Samchundang Pharm. Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.